UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 7, 2024
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 7 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Choi Lai Christina Law |
| 2 | Reason for the notification | |
| a) | Position/status | Member of the Board of Directors |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
Page 2 of 2
| a) |
Description of the financial instrument, type of instrument, |
ADRs | |||
| Identification code | NVO | ||||
| b) | Nature of the transaction | Purchase of ADRs | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 697.24 | 1,400 ADRs | ||||
| d) |
Aggregated information · Aggregated volume · Price |
1,400 ADRs DKK 1,054,226.88 | |||
| e) | Date of the transaction | 2024-11-06 | |||
| f) | Place of the transaction | New York Stock Exchange | |||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
|
Ambre James-Brown +45 3079 9289 |
Liz Skrbkova (US) +1 609 917 0632 |
| Investors: | |
|
Jacob Martin Wiborg Rode +45 3075 5956 |
David Heiberg Landsted +45 3077 6915 |
|
Sina Meyer +45 3079 6656 |
Frederik Taylor Pitter +1 609 613 0568 |
Ida Schaap Melvold
+45 3077 5649
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 81 / 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: November 7, 2024 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen Chief Executive Officer |